Aura Biosciences, Inc.
AURA
$0.28
Change (1 day)
$12.38
Year High
$6.63
Year Low
Categories
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Aura Biosciences, Inc. (AURA)
P/B ratio as of 2023: 1.55
According to Aura Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.55. At the end of 2022 the company had a P/B ratio of 1.61.
P/B ratio history for Aura Biosciences, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.55 |
| 2022 | 1.61 |
| 2021 | 3.26 |
| 2020 | -3.98 |
| 2019 | -4.95 |